DMSO Efficacy in IC/PBS Patients During and After Treatment

Efficacy of DMSO Cocktail Treatment in Interstitial Cystitis Patients During and After Treatment

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01074567

Enrollment

Registered

2010-02-24

Start date

2009-12-31

Completion date

2012-12-31

Last updated

2011-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystitis, Interstitial

Brief summary

The purpose of this study is to examine the efficacy of dimethylsulphoxide (DMSO) cocktail in patients with interstitial cystitis during the treatment period (12 weeks) and after it (at 6 weeks, 3, 6 and 12 month).

Detailed description

The modern treatment of IC is a multi-modal treatment which includes behavioural treatment, physiotherapy of the pelvic floor musculature, oral medication (e.g. Amitryptiline) and intra-vesical instillation (e.g. DMSO, steroids, heparin). These treatments were found to be effective in a number of studies and are approved by the FDA. However, the optimal duration of intra-vesical instilation is not known. All patients with IC (according to the international continence society criteria) will receive 12 weekly intra-vesical instillation of DMSO. All patients will fill an O'leary-Sant questionaire and a urination diary before treatment, after 3, 6, 9 and 12 treatments and at 6 weeks, 3, 6 and 12 month after the end to the treatment.

Interventions

DRUGDMSO cocktail

intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with IC according to International Continence Society: * more than 6 month of pelvic pain * urinary frequency, urgency, dyspareunia

Exclusion criteria

* genitourinary tract infection * known genitourinary malformation

Design outcomes

Primary

Measure	Time frame
O'leary-Sant interstitial cystitis symptom and problem questionaire	before treatment, at 3, 6, 9 and 12 treatments, 6 weeks, 3, 6, 12 month after last treatment

Secondary

Measure	Time frame
urination diary	before treatment, at 3, 6, 9 and 12 treatments, 6 weeks, 3, 6, 12 month after last treatment

Countries

Israel

Contacts

Primary ContactKobi Stav, MD

stavkobi@gmail.com+972-8-9779400

Backup ContactMiki Haifler, MD

mikihaifler@gmail.com+972-8-9401

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026